| Literature DB >> 27587620 |
Steven M Horwitz1, Andrew D Zelenetz1, Leo I Gordon1, William G Wierda1, Jeremy S Abramson1, Ranjana H Advani1, C Babis Andreadis1, Nancy Bartlett1, John C Byrd1, Luis E Fayad1, Richard I Fisher1, Martha J Glenn1, Thomas M Habermann1, Nancy Lee Harris1, Francisco Hernandez-Ilizaliturri1, Richard T Hoppe1, Mark S Kaminski1, Christopher R Kelsey1, Youn H Kim1, Susan Krivacic1, Ann S LaCasce1, Matthew Lunning1, Auayporn Nademanee1, Oliver Press1, Rachel Rabinovitch1, Nishitha Reddy1, Erin Reid1, Kenneth Roberts1, Ayman A Saad1, Lubomir Sokol1, Lode J Swinnen1, Julie M Vose1, Joachim Yahalom1, Nadeem Zafar1, Mary Dwyer1, Hema Sundar1, Pierluigi Porcu1.
Abstract
Peripheral T-cell lymphomas (PTCLs) represent a relatively uncommon heterogeneous group of non-Hodgkin's lymphomas (NHLs) with an aggressive clinical course and poor prognosis. Anthracycline-based multiagent chemotherapy with or without radiation therapy followed by first-line consolidation with high-dose therapy followed by autologous stem cell rescue (HDT/ASCR) is the standard approach to most of the patients with newly diagnosed PTCL. Relapsed or refractory disease is managed with second-line systemic therapy followed by HDT/ASCR or allogeneic stem cell transplant, based on the patient's eligibility for transplant. In recent years, several newer agents have shown significant activity in patients with relapsed or refractory disease across all 4 subtypes of PTCL. These NCCN Guideline Insights highlight the important updates to the NCCN Guidelines for NHL, specific to the management of patients with relapsed or refractory PTCL.Entities:
Mesh：
Year: 2016 PMID： 27587620 DOI： 10.6004/jnccn.2016.0117
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908